Introduction {#sec1-1}
============

*Escherichia coli* (*E. coli*) took the highest position in causative gram-negative bacterium from bloodstream infection (BSIs) patients in Asia region \[[@ref1]\]. It led to severe infections with a high rate of shock and mortality \[[@ref2]\]. Currently, the worldwide incidence of *E. coli* BSI is still increasing over time \[[@ref3]\] with the overall incidence increased year on year \[[@ref4]\] that suggested an increasing burden of disease \[[@ref5]\]. The estimation of infections worldwide showed that third-generation cephalosporin-resistant *E. coli* and *K. pneumoniae* caused 6.4 million (interval estimate 3.5-9.2) BSIs and 50.1 million (27.5-72.8) serious infections in 2014\[[@ref6]\]. In addition, it was difficult to treat because of the emergence of multi-drug resistance (MDR) of *E. coli* \[[@ref7]\]. Thus, evaluating antibiotic susceptibility is essential to decide what types of antibiotics and what appropriate doses that improving treatment efficiency and minimizing the antibiotic resistance rate. Over 20 years, the susceptibility of *E. Coli* BSIs was alarmed with the prevalence of antimicrobial-resistant isolates was increased \[[@ref8]\]. In these cases, the patients had a worse prognosis with partial effect on correct empirical treatment \[[@ref9]\]. Antimicrobial resistance-related encoding gene in each *E. coli* strain. Extended-spectrum β-lactamases (ESBLs) was one of the most important genes \[[@ref10]\]. It minimized the antibiotic efficiency in treatment \[[@ref11]\]. Besides, the ability of inter-transmission within different *E. Coli* strains and transmission between *E. Coli* and other bacteria led to the state of becoming widespread resistance genes around the world. It becomes public-health concern \[[@ref12]\] with increasing burden and cost of hospital-acquired infections \[[@ref13]\], \[[@ref14]\].

In Vietnam, there was one study in Northern Vietnam showed 25.1% of ESBLs among *Enterobacteriaceae* causing BSIs \[[@ref15]\] but there are still limited studies in Northern Vietnam. Thus, this study aims to determine the antibiotic resistance profile and characteristics of subtypes genes in *Escherichia coli* causing bloodstream infections in Northern Vietnam.

Materials and Methods {#sec1-2}
=====================

The cross-sectional study was done in the period from 12/2012 to 6/2014 in two tertiary hospitals in Northern Vietnam (National Hospital of Tropical Diseases and 103 Military Hospital). Isolating from hospitalized BSIs patients in two hospitals 56 *E. coli* strains were inoculated in BHI Broth with 20% glycerol after being identified at the labs of these two hospitals.

*Antimicrobial susceptibility assessed through* MIC test by VITEK^®^2 Compact (BioMérieux, France and provided by DEKA *Limited Liability Company)* standardized by CLSI \[[@ref16]\]. Antibiotics which has been used are *were (with number coding - abbreviation):* amikacin (1-AK), ampicillin (2-AM), ceftazidime (3-CAZ), ciprofloxacin (4-CIP), ceftriaxone (5-CRO), cefazolin (6-CZ), doripenem (7-DOR), ertapenem (8-ETP), cefepime (9-FEP), gentamycin (10-GM), levofloxacin (11-LVX), ampicillin/sulbactam (12-SAM), trimethoprim/sulfamethoxazole (13-SXT), tobramycin (14-TM) , piperacillin/tazobactam (15-TZP).

Using QIAamp DNA Mini Kit (USA) for DNA extraction (including isolation and quantification), we performed the experimental procedure according to manufacturer's instruction. PCR amplification performed in PCR master mix (Invitrogen -- USA) that consisted of 200 µM of each dNTPs (dATP, dCTP, dGTP, dTTP), 100 pM primers, 1 U Taq DNA polymerase, 10 mM Tris-HCl, 50 mM KCl, 1,5 mM MgCl~2~ and 10 µl DNA template. Specific primers for *bla*~TEM~, *bla*~SHV~, *bla*~CTX-M~, *bla*~PER~ genes showed in [Table 1](#T1){ref-type="table"}. The experiments were performed using the protocol with 30 cycles that each of them consisted of 3 steps including denaturing (95°C for 30 seconds), annealing (58, 57, 60, 54°C for 30 seconds), elongating (72°C for 1 minute). PCR products were performed electrophoresis, imaged routinely and sequenced. The sequence of PCR products was compared with the original gene's sequence on GenBank to confirm *bla*~TEM~, *bla*~SHV~, *bla*~CTX-M~ and *bla*~PER~ gene.

###### 

Specific primers for blaTEM, blaSHV, blaCTX-M, blaPER genes

  Target gene    Primer                                      Nucleotide sequence (5' -- 3')           Size (bp)   AT (°C)
  -------------- ------------------------------------------- ---------------------------------------- ----------- ---------
  *bla*~TEM~     TEM-F                                       5' -- TGC GGT ATT ATC CCG TGT TG -- 3'   300         52.2
  TEM-R          5' -- TCG TCG TTT GGT ATG GCT TC -- 3'                                                           
  *bla*~SHV~     SHV-F                                       5' -- TCT CCC TGT TAG CCA CCC TG -- 3'   600         51.2
  SHV-R          5' -- CCA CTG CAG CAG CTG C -- 3'                                                                
  *bla*~CTX-M~   CTX-M-F                                     5' -- CGA TGT GCA GTA CCA GTA A -- 3'    650         60
  CTX-M-R        5' -- TTA GTG ACC AGA ATC AGC GG -- 3'                                                           
  *bla*~PER~     PER-F                                       5' -- ATG AAT GTC ATT ATA AAA GC -- 3'   933         
  PER-R          5' -- TTA ATT TGG GCT TAG GGC AGA A -- 3'                                                        

Statistical Analysis {#sec2-1}
--------------------

The statistical analysis was conducted using the R language \[[@ref17]\]. Graphics also were performed by R language (version 3.5.2). The analysis of such enormous volumes of information in the acquisition of data from 56 strains, each strain companion with subtype genes (three *bla*~TEM~ subtypes, four *bla*~CTX-M~ subtypes, eight *bla*~SHV~ subtypes) and 15 antibiotics with 3 level of resistance (susceptible, intermediate, resistance). For this reason, we used R language to analyze.

Results {#sec1-3}
=======

Clinical characteristics of the patient in this study showed in [Table 2](#T2){ref-type="table"}.

###### 

Clinical characteristics of patients

  ------------------------------- ------------
  Age (subgroup)                  
   16-19                          0 (0)
   20-29                          8 (14.29)
   30-39                          3 (5.36)
   40-49                          9 (16.07)
   50-59                          17 (30.35)
   ≥ 60                           19 (33.93)
  Gender                          
   Male                           37 (66.07)
   Female                         19 (33.93)
  History of medical condition    
   Cirrhosis                      13 (23.21)
   Self-report alcoholism         10 (17.86)
   Diabetes                       8(14.29)
   Hypertension                   6 (10.71)
   Long-term corticosteroid use   4 (7.14)
   Renal failure                  2 (3.57)
   Pregnancy                      2 (3.57)
   Spinal cord injury             1 (1.79)
   Urinary tract stone            1 (1.79)
   Heart failure                  1 (1.79)
   Cancer                         1 (1.79)
   No                             7 (12.5)
  Time to hospitalization         
   \< 5                           40 (71.43)
   5-14                           14 (25.00)
   \> 14                          2 (3.57)
  ------------------------------- ------------

Among 56 *E. coli* strains isolated analyzed, 39.3% strains were identified as producing ESBL. Detail information of sequencing results showed in [Table 3](#T3){ref-type="table"} highlighting three *bla*~TEM~ subtypes (*bla*~TEM~ 1, *bla*~TEM~ 79, *bla*~TEM~ 82), four *bla*~CTX-M~ subtypes (*bla*~CTX-M~-15, *bla*~CTX-M~-73, *bla*~CTX-M~-98, *bla*~CTX-M~-161), and eight *bla*~SHV~ subtypes (*bla*~SHV~-5, *bla*~SHV~-7, *bla*~SHV~-12, *bla*~SHV~-15, *bla*~SH~ -24, *bla*~SHV~-33, *bla*~SHV~-57, *bla*~SHV~-77).

###### 

ESBL-producing E. coli strains and ESBL encoding genes

  Result                                   Number of strains (n = 56) Percentage (%)
  ---------------------------------------- -------------------------------------------
  ESBL-positive                            22 (39.29 %)
  ESBL-negative                            34 (60.71 %)
  *bla*~TEM~                               56
    TEM-1                                  34
    TEM-79                                 19
    TEM-82                                 3
  *bla*~CTX-M~                             43
    CTX-M-15                               12
    CTX-M-73                               11
    CTX-M-98                               17
    CTX-M-161                              3
  *bla*~PER~                               0
  *bla*~SHV~                               16
    SHV-5                                  3
    SHV-7                                  2
    SHV-12                                 6
    SHV-15                                 1
    SHV-24                                 1
    SHV-33                                 1
    SHV-57                                 1
    SHV-77                                 1
  *bla*~TEM~ *+ bla*~CTX-M~                32 (57.2 %)
  *bla*~TEM~ *+ bla*~SHV~                  5 (8.9 %)
  *bla*~TEM~ *+ bla*~SHV~ + *bla*~CTX-M~   11 (19.6 %)

The results of gene analysis revealed that 100% of isolates harbored *bla*~TEM~ gene, but none of them had the *bla*~PER~ gene ([Table 4](#T4){ref-type="table"}). The prevalence of *bla*~CTX-M~ gene of overall strains, ESBL-producing, and non-ESBL-producing were 76.79%, 81.8%, and 73.5%, respectively. The prevalence of *bla*~SHV~ gene among ESBL-producing and non-ESBL-producing strains were 18.2% and 35.3%. More information showed in [Table 4](#T4){ref-type="table"}.

###### 

Encoding gene of ESBL subtypes

  Gene                                     ESBL-positive (n = 22)   ESBL-negative (n = 34)                                  
  ---------------------------------------- ------------------------ ------------------------ ---- ------- ---- ------- ---- -------
  *bla*~PER~                                                                                 22   100                  34   100
  *bla*~TEM~                               22                       100                                   34   100          
  *bla*~TEM~ *+ bla*~CTX-M~                18                       81.82                    4    18.18   25   73.53   9    26.47
  *bla*~TEM~ *+ bla*~SHV~                  4                        18.18                    18   81.82   12   35.29   22   64.71
  *bla*~TEM~ *+ bla*~SHV~ + *bla*~CTX-M~   3                        13.64                    19   86.36   8    23.53   26   76.47

[Figure 1](#F1){ref-type="fig"} showed a high prevalence of resistance to ampicillin (AM-85.7% of strains), trimethoprim/sulfamethoxazole (STX-64.3% of strains), cephazolin (CZ-50% of strains), ciprofloxacin (CP-35.7% of strains) and levofloxacin (LVX-35.7% of strains).

![Antibiotic resistance profile; Antibiotics are 1 to 15 following 15 antibiotic have been coded Amikacin (1-AK); Ampicillin (2-AM); Ceftazidime (3-CAZ); Ciprofloxacin (4-CIP); Ceftriaxone (5-CRO); Cefazolin (6-CZ); Doripenem (7-DOR); Ertapenem (8-ETP); Cefepime (9-FEP); Gentamycin (10-GM); Levofloxacin (11-LVX); Ampicillin/Sulbactam (12-SAM); Trimethoprim/sulfamethoxazole (13-SXT); Tobramycin (14-TM); Piperacillin/Tazobactam (15-TZP)](OAMJMS-7-4393-g001){#F1}

[Figure 2](#F2){ref-type="fig"} showed highly active antibiotics such as doripenem (DOR-96.4% of strains), ertapenem (ETP-94.6% of strains), amikacin (AK-96.4% of strains), and cefepime (PEP-89.3% of strains). In each antibiotic, detail information of genes was shown.

![Antibiotic sensitivity profile; Antibiotics are 1 to 15 following 15 antibiotic have been coded Amikacin (1-AK); Ampicillin (2-AM); Ceftazidime (3-CAZ); Ciprofloxacin (4-CIP); Ceftriaxone (5-CRO); Cefazolin (6-CZ); Doripenem (7-DOR); Ertapenem (8-ETP); Cefepime (9-FEP); Gentamycin (10-GM); Levofloxacin (11-LVX); Ampicillin/Sulbactam (12-SAM); Trimethoprim/sulfamethoxazole (13-SXT); Tobramycin (14-TM); Piperacillin/Tazobactam (15-TZP)](OAMJMS-7-4393-g002){#F2}

[Figure 3](#F3){ref-type="fig"} showed that in patients who carried gene had high rate of antibiotic resistance with the main antibiotics were ceftazidime (3-CAZ), cefazolin (6-CZ), doripenem (7-DOR), gentamycin (10-GM), levofloxacin (11-LVX), ampicillin/sulbactam (12-SAM), trimethoprim/sulfamethoxazole (13-SXT) in line with *bla*~CTX-M~ gene with the same allocation. Tobramycin (14-TM) with intermediate response had *bla*~SHV~ and *bla*~TEM~ as main genes. [Figure 3](#F3){ref-type="fig"} supported [Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} to visualize the association between gene and antibiotic resistance.

![The antibiotic resistance level with genes. Gen antibiotic is 1 to 5 following CTX-M gene, ESBL gene, PER gene, SHV gene and TEM gene; Anti -- biotic RSI is 1 to 3 following R (resistance), S (sensitive), I (intermediate); Antibiotics are 1 to 15 following 15 antibiotic have been coded Amikacin (1-AK), Ampicillin (2-AM), Ceftazidime (3-CAZ), Ciprofloxacin (4-CIP), Ceftriaxone (5-CRO), Cefazolin (6-CZ), Doripenem (7-DOR), Ertapenem (8-ETP), Cefepime (9-FEP), Gentamycin (10-GM), Levofloxacin (11-LVX), Ampicillin/Sulbactam (12-SAM), Trimethoprim/sulfamethoxazole (13-SXT), Tobramycin (14-TM) , Piperacillin/Tazobactam (15-TZP)](OAMJMS-7-4393-g003){#F3}

[Table 5](#T5){ref-type="table"} clarified the detail of antibiotic resistance with the ESBL gene. While ESBL-positive strains were highly resistant to ampicillin (AM), ceftriaxone (CRO), cephazolin (CZ), and trimethoprim/sulfamethoxazole (SXT) at the rate of 100%, 100%, 100%, and 81.8%, respectively, ESBL-negative strains had a lower prevalence of resistance to these agents at the rate of 76.5%, 11.8%, 17.7%, and 53%, respectively. Both groups were susceptible to doripenem (DOR), ertapenem (ETP), and amikacin (AK) at the rate of more than 90%.

###### 

The antibiotic resistance profile of ESBL subtype

  Antimicrobial Agents             ESBL-positive (n = 22)   ESBL-negative (n = 34)                                         
  -------------------------------- ------------------------ ------------------------ ------------ ------------ ----------- ------------
  Ampicilin                                                                          22 (100)     7 (20.59)    1 (2.94)    26 (76.47)
  Ceftriaxone                                                                        22 (100)     30 (84.24)               4 (11.76)
  Cephazolin                                                                         22 (100)     27 (79.41)   1 (2.94)    6 (17.65)
  Trimethoprim/ sulfamethoxazole   4 (18.18)                                         18 (81.82)   16 (47.06)               18 (52.94)
  Ampicilin/sulbactam              10 (45.45)                                        12 (54.55)   13 (38.24)   8 (23.53)   13 (38.24)
  Ciprofloxacin                    11 (50)                                           11 (50)      25 (73.53)               9 (26.47)
  Levofloxacin                     11 (50)                                           11 (50)      25 (73.53)               9 (26.47)
  Piperacilline/ Tazobactam        11 (73.33)               2 (13.33)                2 (13.33)    19 (82.61)   1 (4.35)    3 (13.04)
  Ceftazidime                      15 (68.18)                                        7 (31.82)    30 (88.24)               4 (11.76)
  Cefepime                         18 (81.82)               1 (4.55)                 3 (13.64)    22 (94.12)               2 (5.88)
  Doripenem                        22 (100)                                                       32 (94.12)               2 (5.88)
  Ertapenem                        21 (95.45)               1 (4.55)                 1 (4.55)     32 (94.12)               2 (5.88)
  Amikacin                         22 (100)                                                       32 (94.12)               2 (5.88)
  Gentamycin                       15 (68.18)                                        7 (31.82)    25 (73.53)   1 (2.94)    8 (23.53)
  Tobramycin                       14 (63.64)               5 (22.73)                3 (13.64)    25 (73.53)   7 (20.59)   2 (5.88)

Discussion {#sec1-4}
==========

ESBL-producing *E. coli* is common genotypes and its incidence varies from region to region. ESBLs are typically inhibitor-susceptible B-lactamases that are encoded by mobile genes with the *bla*~CTX-M~, *bla*~SHV~, and *bla*~TEM~ families were the most frequently. In our study, among 56 *E. coli* strains have been analyzed, 39.3% strains were identified as ESBL-producing. Our finding is higher than that of study in Northern, Vietnam (25.1% of strains produced ESBL among *Enterobacteriaceae*) \[[@ref15]\]. Comparing with other countries, it is higher than Singapore (33%) \[[@ref18]\], Chile (23.8%) and Brazil (12.8%) but lower than that of India (60%), Hong Kong (48%) \[[@ref18]\] Mexico (48.4%) \[[@ref19]\]. All cases with ESBL-producing *E. Coli* had *bla*~TEM~ gene and the 100% resistance to ampicillin was found that in line with the present study \[[@ref20]\].

Our results about *bla*~CTX-M~ gene also corroborated another study that reported *bla*~CTX-M~ bla (beta-lactamase) gene was common in all the ESBL isolates \[[@ref21]\]. This result is also in agreement with study Gurntke et al., of that among 19% ESBL-positive cases, *bla*~CTX-M~-15 was the most common genotypes (60%), followed by *bla*~SHV~-5 (27%) \[[@ref22]\]. Other studies showed the same results with *bla*~CTX-M~-14 (48% of the isolates) were the most frequent ESBL \[[@ref11]\], \[[@ref23]\]. It was observed that the predominant of subtypes *bla*~CTX-M~ gene was diverse from study to study. Analyzing 552 isolates from BSIs that resistance to third-generation cephalosporin showed more detail with *bla*~CTX-M~-15 (50%), *bla*~CTX-M~-14 (14%), *bla*~CTX-M~-27 (11%) and *bla*~CTX-M~-101 (5%) \[[@ref24]\].

ESBL-producing *E. Coli* in BSIs have been shown a substantial increase in the 21^st^ century \[[@ref25]\]. Besides that, its burden was growing worldwide \[[@ref26]\]. Finding the appropriate therapy became crucial and carbapenems emerged as 'best therapy' for ESBL-producing bacteria \[[@ref25]\]. But in the time of antibiotics and resistance becoming popular, *E. Coli* also starts resistance to carbapenem that leading a high financial burden and increased mortality \[[@ref27]\].

The knowledge of antibiotic resistance profile is key in clinical practice. The high rate of resistance to some routine antibiotic agents which were commonly used in most hospitals in our area was provided in this study. The results also showed that amikacin and carbapenems (doripenem and ertapenem) emerged as choices for empiric therapy instead. Sinha et al., showed similar findings with high prevalence of ESBL-positive, high rate of resistance to ampicillin (86%), ceftriaxone (80.6%), and fluoroquinolones (80%) and the clear choice for empirical treatment were carbapenems in these cases \[[@ref21]\].

Knowing the risk factors of antibiotic resistance is crucial for management strategy. The time before hospitalization was an only independent risk factor among ESBL in BSIs \[[@ref28]\] while previous use of oxyimino-beta-lactams was the only modifiable risk factor among nosocomial BSIs \[[@ref11]\]. In our study, ESBL encoding genes showed high correlation with antibiotic resistance.

While ESBL-positive strains were highly resistant to ampicillin, ceftriaxone, cephazolin, and trimethoprim/sulfamethoxazole at the rate of 100%, 100%, 100%, and 81.8%, respectively, ESBL-negative strains showed a lower prevalence of resistance to these agents at the rate of 76.5%, 11.8%, 17.7%, and 53%, respectively. Both groups were susceptible to doripenem, ertapenem, and amikacin at the rate of more than 90%. This finding was similar to the study in Finland from 1999 to 2013 that showed most (88%) of the isolates reported as non-susceptible to third-generation cephalosporins had ESBL phenotype \[[@ref29]\].

In conclusion, in *Escherichia coli* causing bloodstream infections, antibiotic resistance was higher in ampicillin, trimethoprim/sulfamethoxazole and cephazolin Antibiotics was highly susceptible including doripenem, ertapenem, amikacin, and cefepime.

A high prevalence of with three subtypes and with four subtypes**.** showed more subtypes (eight) but lower prevalence.
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